Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biosergen ABFRA:8N10 18 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates FRA:8N10 with a GF Score™ of 18/100. Among 703 Biotechnology companies, Biosergen AB ranks worse than 142247.37% on this metric.
The historical rank and industry rank for Biosergen AB's Days Payable or its related term are showing as below:
During the past 6 years, Biosergen AB's highest Days Payable was 12165.98. The lowest was 3405.47. And the median was 8837.56.
FRA:8N10's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
Biosergen AB's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
stayed the same
The historical data trend for Biosergen AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8N10 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Biosergen AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosergen AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biosergen AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Biosergen AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biosergen AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosergen AB (FRA:8N10) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biosergen AB and its competitors. Over the past decade, Biosergen AB's Days Payable has ranged from 3,405.47 to 12,165.98. According to the industry distribution chart, Biosergen AB ranks #999999 out of 703 companies in the Biotechnology industry.
Is Biosergen AB's Days Payable too high?
Biosergen AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 3,405.47 to a high of 12,165.98. Based on the distribution chart, Biosergen AB ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biosergen AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biosergen AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biosergen AB ranks #999999 out of 703 companies for Days Payable. This places Biosergen AB in the lower half of its industry. The industry median Days Payable is 112.84. Historically, Biosergen AB's own Days Payable has ranged from 3,405.47 to 12,165.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biosergen AB and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosergen AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosergen AB stock overvalued right now?
Biosergen AB (FRA:8N10) has a current Days Payable of 0.00. The current Days Payable is 0.00. Biosergen AB's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biosergen AB (FRA:8N10), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
18GF Score
Get the complete analysis for FRA:8N10
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8N10 has been successfully added to your 
